Cargando…
Nanomedicine for Imaging and Therapy of Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma has the worst outcome among all cancer types, with a 5-year survival rate as low as 10%. The lethal nature of this cancer is a result of its silent onset, resistance to therapies, and rapid spreading. As a result, most patients remain asymptomatic and present at diagnosis w...
Autores principales: | Brachi, Giulia, Bussolino, Federico, Ciardelli, Gianluca, Mattu, Clara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880757/ https://www.ncbi.nlm.nih.gov/pubmed/31824928 http://dx.doi.org/10.3389/fbioe.2019.00307 |
Ejemplares similares
-
Nanomedicine for the Diagnosis and Therapy of COVID-19
por: Wang, Yingruo, et al.
Publicado: (2021) -
Editorial: Nanomedicine for Deep-Tissue High-Resolution Bio-Imaging and Non-invasive Therapy
por: Gao, Yu, et al.
Publicado: (2020) -
Mitochondria-Targeted Nanomedicine for Enhanced Efficacy of Cancer Therapy
por: Gao, Yan, et al.
Publicado: (2021) -
Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy
por: Guan, Mengqi, et al.
Publicado: (2021) -
Theranostic Nanomedicine for Malignant Gliomas
por: d'Angelo, Michele, et al.
Publicado: (2019)